Gottlieb takes aim at pharma and CROs in call to reform trials

15 March 2019

The outgoing US Food and Drug Administration (FDA) Commissioner Scott Gottlieb (pictured above) has called on other players in the drug development ecosystem to play their part in the modernization of clinical trials.

Dr Gottlieb sees the reform of trials as a priority for his agency and essential to the advance of precision medicine, with more diseases being redefined based on genomic subtype, researchers having more new targets and increasing opportunities to precisely modulate or even repair the basic biological drivers of illness.

Potential for earlier regulatory assessment

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK